Ottawa Hospital Research Institute

Dr. Scott C. Morgan

Claim this profile

Ottawa Hospital and Cancer Center-General Campus

Studies Prostate Cancer
Studies Prostate Adenocarcinoma
7 reported clinical trials
26 drugs studied

Area of expertise

1

Prostate Cancer

Scott C. Morgan has run 6 trials for Prostate Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I
2

Prostate Adenocarcinoma

Scott C. Morgan has run 2 trials for Prostate Adenocarcinoma.

Affiliated Hospitals

Image of trial facility.

Ottawa Hospital And Cancer Center-General Campus

Image of trial facility.

Ottawa Hospital Research Institute

Clinical Trials Scott C. Morgan is currently running

Image of trial facility.

Prostate SBRT + Triptorelin

for Prostate Cancer

External beam radiotherapy combined with androgen deprivation therapy is a standard treatment option for localized prostate cancer. The current standard involves delivering radiotherapy uniformly throughout the prostate gland in daily fractions, five days per week, for approximately four weeks. In this study, radiotherapy will be delivered using an ultra-hypofractionated approach in three larger fractions on alternating days over one week Multiparametric magnetic resonance imaging will be used to guide focal dose escalation to parts of the gland harboring tumor, which could potentially reduce the risk of cancer recurrence compared to standard dose of radiotherapy. The aim of this study is to confirm that this approach can be delivered safely, that is, with rates of urinary and bowel side effects at 1 year of follow-up that are not significantly greater than the current standard.

Recruiting

1 award

Phase 2

10 criteria

Image of trial facility.

Shorter vs Usual Radiation Therapy

for Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.

Recruiting

2 awards

Phase 3

10 criteria

More about Scott C. Morgan

Clinical Trial Related

5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Scott C. Morgan has experience with

  • Prostate SBRT With Focal Boost
  • Triptorelin Injection
  • Ipilimumab/Nivolumab
  • SBRT
  • Darolutamide
  • External Beam Radiotherapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Scott C. Morgan specialize in?

Is Scott C. Morgan currently recruiting for clinical trials?

Are there any treatments that Scott C. Morgan has studied deeply?

What is the best way to schedule an appointment with Scott C. Morgan?

What is the office address of Scott C. Morgan?

Is there any support for travel costs?